He read through an hour of sleep journals before finding anything actionable. Considered, briefly, that maybe this was just what your fifties felt like. Then his annual physical came back with blood pressure he’d never had before, his fasting glucose was creeping up, and his wife mentioned — gently — that he seemed like a different person. Flatter. Less present. Less himself.
It took Tom two more years to connect those threads back to his disrupted melatonin system, which had been trying to tell him something was wrong by waking him at the exact same hour every night.
Melatonin, in the popular imagination, is a sleep supplement. The $0.12 gummy taken at 10 PM to fall asleep faster on a flight. That conception is so far short of what melatonin actually does in the body that it borders on misleading.
Melatonin is the body’s chemical darkness signal — the biochemical version of night itself — and in that role it coordinates the entire biological timing system that synchronizes sleep, metabolism, immunity, hormonal secretion, cell division, DNA repair, and antioxidant defense. Calling it a “sleep hormone” is like calling the conductor of an orchestra “the person who waves the stick.”
Understanding melatonin as a master hormone — with specific mechanisms in cellular protection, immune regulation, reproductive timing, cardiovascular function, and tumor suppression — changes how light exposure, sleep timing, seasonal rhythms, and the chronic circadian disruption of modern life should be thought about. This isn’t another round of sleep hygiene tips already heard a dozen times.
It’s the story of a hormone made in one very specific spot in the brain for one very specific purpose, which modern lighting and modern lifestyle are systematically taking apart, with consequences reaching into nearly every domain of physical health.
Where Melatonin Comes From and How It Works
Melatonin is made primarily in the pineal gland, a pea-sized neuroendocrine structure sitting dead center in the brain between the two hemispheres — the same structure René Descartes famously, and incorrectly, called the seat of the soul.
(Wrong about the soul. Not entirely wrong that the pineal gland is unusual — it’s one of the few brain structures not protected by the blood-brain barrier, which makes it exquisitely sensitive to circulating signals.) The pineal gland converts serotonin to melatonin in two enzymatic steps: arylalkylamine N-acetyltransferase (AA-NAT), rate-limiting and light-sensitive, and hydroxyindole-O-methyltransferase (HIOMT).
Synthesis depends entirely on darkness. Photoreceptors in the retina — including a specific type called intrinsically photosensitive retinal ganglion cells (ipRGCs), which contain melanopsin and respond most strongly to short-wavelength blue light — send light signals via the retinohypothalamic tract to the suprachiasmatic nucleus (SCN) of the hypothalamus.
The SCN is the brain’s master circadian clock — a small bilateral nucleus of roughly 20,000 neurons maintaining a 24-hour oscillation through interlocking molecular feedback loops involving clock genes (CLOCK, BMAL1, PER1/2/3, CRY1/2). It sends darkness-dependent signals to the pineal gland releasing the inhibition on melatonin synthesis, letting melatonin rise once it’s dark.
Melatonin’s rhythm is one of the most precisely timed physiological events in the body. In healthy people with normal circadian rhythms and appropriate light-dark exposure, melatonin begins rising roughly 2 hours before habitual sleep time — a phase called Dim Light Melatonin Onset (DLMO), the gold-standard biomarker of circadian phase. It peaks around 2-3 AM, then drops to essentially undetectable daytime levels by mid-morning.
This nighttime window of elevated melatonin is how the body coordinates timing-sensitive processes: the initial rise triggers sleep onset, the sustained nocturnal elevation supports deep sleep maintenance and growth hormone release, and the morning decline plays into the cortisol awakening response and metabolic activation.
Melatonin works through two primary receptors, MT1 and MT2, spread throughout the brain and peripheral tissues. MT1 activation drives sleep induction and inhibits neuronal firing in the SCN. MT2 activation leans more toward phase-shifting the circadian clock — which is why melatonin works better for jet lag, resetting the clock, than for insomnia maintenance, staying asleep.
In peripheral tissues, MT1 and MT2 receptors on immune cells, cardiovascular tissue, reproductive organs, and gastrointestinal cells carry out melatonin’s effects in those systems — effects entirely independent of its central sleep-promoting role, and ones that keep happening whether or not the person is actually asleep.
Light at Night: The Melatonin Suppression Problem
The most consequential modern interference with melatonin is artificial light at night, which hijacks the same blue-light-sensitivity pathway that evolved to read sunlight as the circadian time-giver — now triggering melatonin suppression at times and intensities with no evolutionary precedent whatsoever.
The biological machinery built to respond to the setting sun and true nighttime darkness now runs into LED screens, smartphones, and indoor LED lighting throwing off enough blue-spectrum light to substantially suppress melatonin, through mechanisms that are both well characterized and remarkably easy to trigger by accident.
Melanopsin-containing ipRGCs are most sensitive to light in the 460-480 nanometer range — the peak blue-green spectrum. That sensitivity has a strikingly low threshold: a 2001 study by Brainard et al. in the Journal of Neuroscience found relatively modest exposures — 100 lux, roughly the brightness of typical indoor home lighting — could substantially suppress melatonin. Smartphone screens at typical nighttime brightness emit enough blue light to suppress melatonin by 50% or more in controlled lab studies.
A 2014 study in PNAS found people who read on light-emitting devices before bed had DLMO shifted 1.5 hours later, took 10 minutes longer to fall asleep, got less REM sleep, and showed reduced morning alertness compared to those reading printed books — effects that persisted for days after the reading period ended, suggesting cumulative circadian disruption rather than just an acute sleep-onset hit.
The dose-response relationships matter for calibrating practical advice. Melatonin’s suppressive response to light is a function of wavelength (blue most suppressive), intensity (higher lux more suppressive), duration (longer exposure more suppressive), and timing relative to circadian phase — light in the hours after DLMO is most suppressive, light in the hours before is most phase-shifting.
Wearing blue-light-blocking glasses — amber or orange lenses filtering wavelengths below 550 nm — for 2-3 hours before habitual sleep time has been shown in randomized controlled trials to meaningfully blunt melatonin suppression and improve sleep quality in people using screens in the evening.
Shift work represents the far end of the melatonin disruption spectrum, and the health data from shift workers is a sobering look at what chronic disruption at scale does to human health. Shift work associates with higher rates of metabolic syndrome, type 2 diabetes, cardiovascular disease, cancer (particularly breast and colorectal), mood disorders, gastrointestinal disease, and impaired immune function.
The World Health Organization’s International Agency for Research on Cancer classified shift work involving circadian disruption as a probable human carcinogen back in 2007 — a classification built on the convergence of animal evidence showing melatonin’s tumor-suppressive effects, epidemiological evidence of elevated cancer rates in shift workers, and mechanistic evidence tying melatonin suppression to reduced tumor suppressor gene expression.
Melatonin as Antioxidant: Beyond Sleep
One of melatonin’s most clinically significant and least publicly understood roles is as a direct antioxidant and inducer of antioxidant enzymes. It’s a remarkably potent scavenger of reactive oxygen species (ROS) and reactive nitrogen species (RNS) — the molecular byproducts of normal metabolism that, in excess, drive aging and chronic disease. This role alone reframes melatonin from sleep hormone to nighttime cellular repair and maintenance signal.
Melatonin neutralizes the hydroxyl radical — the most reactive and damaging of the ROS species — without itself turning pro-oxidant, a property that sets it apart from conventional antioxidants like vitamin C and vitamin E, which can flip pro-oxidant under certain conditions. More significant still, melatonin induces expression of the major antioxidant enzymes: superoxide dismutase (SOD), catalase, and glutathione peroxidase — enzymes providing sustained antioxidant protection well past melatonin’s own direct scavenging.
A 2006 review in the Journal of Pineal Research called this a “cascade antioxidant response” — melatonin doesn’t just neutralize free radicals directly, it switches on the body’s own antioxidant defense systems to keep doing it.
The mitochondrial connection is particularly notable. Melatonin accumulates in mitochondria at concentrations substantially higher than in the surrounding cytoplasm, apparently produced locally from tryptophan right there in the mitochondrial matrix — not only imported from pineal secretion. Mitochondria are the primary site of cellular ROS production, from electron transport chain leakage, and are themselves especially vulnerable to oxidative damage.
Melatonin’s mitochondrial concentration and antioxidant activity amount to a localized protection system for the organelles most exposed to, and most consequentially damaged by, oxidative stress.
This antioxidant role has implications for cancer biology, cardiovascular disease, and neurological aging reaching well past sleep. Oxidative DNA damage during cell division drives carcinogenic mutations; melatonin’s nighttime antioxidant activity during the cell-division phase may reduce the rate of those oxidative mutations, consistent with the epidemiological data on melatonin and cancer risk.
Cardiovascular oxidative stress — particularly oxidation of LDL cholesterol into oxidized LDL, the form that initiates atherosclerosis — is modulated by melatonin levels. Neurological aging involves progressive mitochondrial dysfunction with accumulating oxidative damage in neurons; melatonin’s mitochondrial antioxidant function offers one mechanism through which the consistent link between sleep quality and cognitive aging in epidemiological studies might actually operate.
Melatonin and the Immune System
Immune cells throughout the body express MT1 and MT2 receptors and produce melatonin locally through the same enzymatic pathway as the pineal gland. Natural killer cells, T-helper cells, T-cytotoxic cells, and B lymphocytes are all melatonin-responsive, with melatonin generally boosting their activity and proliferation.
The sleep-immune relationship most people have already noticed empirically — get sick when sleep-deprived, recover faster when sleeping more — is mechanistically grounded partly in the melatonin-immune axis: its nocturnal rise coordinates immune cell activity to optimize pathogen surveillance and clearance during the overnight maintenance window.
Melatonin’s effects on inflammatory signaling matter a great deal for chronic disease. It inhibits NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells), the master transcription factor driving pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6. NF-κB stays chronically activated in metabolic syndrome, obesity, cardiovascular disease, and neurodegenerative disease — a state called “inflammaging,” the low-grade inflammatory component of aging itself. By inhibiting NF-κB overnight, melatonin provides a nightly damping signal on systemic inflammatory tone.
When melatonin is chronically suppressed by light at night, that nightly anti-inflammatory signal weakens, potentially contributing to the elevated inflammatory markers seen in people with disrupted sleep and circadian rhythms.
The COVID-19 pandemic generated notable interest in melatonin’s immune and anti-inflammatory effects, with some early observational data suggesting melatonin use was associated with lower COVID-19 severity and infection rates in certain populations. That evidence remains preliminary and isn’t sufficient to recommend melatonin as a COVID therapeutic, but it’s consistent with melatonin’s documented NF-κB-inhibiting and immune-modulating properties, which would plausibly attenuate the cytokine storm driving severe COVID-19 pathology.
The mechanistic rationale holds up even where the clinical evidence remains incomplete.
Melatonin and Cancer: The Night Shift Evidence
The melatonin-cancer relationship is one of the most consequential parts of melatonin biology and one of the most robustly supported by converging evidence from multiple research directions. The core evidence comes from three angles: elevated cancer rates in shift workers, direct tumor-suppressive effects of melatonin in animal and cell models, and the finding that total blindness — associated with uninhibited melatonin production — correlates with reduced cancer incidence.
The finding that totally blind women have lower breast cancer rates than sighted women is conceptually elegant, because it directly tests the melatonin hypothesis without the lifestyle confounders that complicate shift work studies. People who are totally blind can’t have their melatonin suppressed by light, because no light reaches the retina at all — they maintain round-the-clock melatonin production in a free-running pattern rather than the light-entrained, daytime-suppressed pattern the sighted population runs on.
A 2001 study in Epidemiology found totally blind women had roughly half the breast cancer incidence of sighted women — a dramatic difference that specifically implicates light-driven melatonin suppression as a mechanism in breast cancer risk.
Melatonin’s direct anti-tumor mechanisms are multiple and well characterized. It reduces production of linoleic acid metabolites that stimulate cancer cell proliferation, particularly in breast cancer cells. It inhibits telomerase, the enzyme that extends telomeres and enables unlimited cell division in cancer cells. It downregulates estrogen receptor expression in breast cancer cells, reducing estrogen-driven tumor growth — which may be the specific mechanism behind the lower risk of estrogen-receptor-positive breast cancer in blind women.
It promotes apoptosis, programmed cell death, in cancer cells through effects on mitochondrial membrane potential and cytochrome c release. And through its antioxidant function, it reduces the oxidative DNA damage that initiates carcinogenic mutations in the first place.
The clinical translation of all this isn’t that melatonin supplements cure cancer — the doses used in cell and animal studies are pharmacological, not physiological, and evidence for melatonin supplementation as a human cancer treatment remains preliminary.
The actual translation is that maintaining strong nighttime melatonin secretion through appropriate darkness during sleep — reducing evening light exposure, using blackout curtains, keeping a consistent sleep schedule — preserves the nightly endogenous melatonin surge that provides this protection. Prevention through circadian optimization, more effective and more sustainable than any supplement could be.
Melatonin and Metabolic Health
Melatonin’s metabolic effects connect the cancer and sleep biology to cardiovascular and metabolic disease epidemiology, making circadian optimization directly relevant to anyone concerned about metabolic health — sleep complaints or none.
Melatonin has direct effects on pancreatic function through MT1 and MT2 receptors expressed on pancreatic beta cells. It inhibits insulin secretion during the nighttime period, which sounds counterproductive until the logic clicks into place: during the overnight fast, insulin should be low to allow fat mobilization, and melatonin’s beta-cell-inhibiting effect contributes to the overnight low-insulin state that lets fat burning and growth hormone activity run.
The problem shows up when people eat late at night or load up on evening carbohydrates: combine melatonin-mediated beta cell inhibition with a glucose load, and the result is disproportionate hyperglycemia, because the beta cells are running in “nighttime suppressed” mode when asked to handle a meal. This is the biological basis for the well-established finding that the identical caloric meal eaten in the morning produces a substantially lower glucose response than the same meal eaten in the evening.
Genetic variants in melatonin receptor genes add further evidence for melatonin’s metabolic role. A common variant in the MT2 receptor gene (MTNR1B) is one of the strongest genetic predictors of type 2 diabetes risk identified in genome-wide association studies — people carrying the high-risk allele have higher fasting glucose, impaired first-phase insulin secretion, and roughly 20% higher lifetime diabetes risk.
That genetic association confirms the melatonin-beta cell regulatory axis is functionally significant for metabolic health at the population level, not merely in controlled experiments.
Melatonin also shapes adipose tissue function through effects on fat cell differentiation and lipolysis. MT1 receptor activation in adipocytes reduces lipolysis at night, consistent with the overnight metabolic quiescence that characterizes healthy circadian metabolism, while MT2 activation in brown adipose tissue increases thermogenesis and energy expenditure. The net effect of strong nighttime melatonin is coordinated adipose tissue activity that supports appropriate cycling of metabolic fuel between storage and use.
Disrupted melatonin signaling in adipose tissue — from chronic light at night, shift work, or aging-related melatonin decline — contributes to the adipose tissue dysfunction seen in obesity and metabolic syndrome.
Age-Related Melatonin Decline and How to Slow It
This age-related decline comes partly from pineal gland calcification — calcium deposits visible on head CT scans, present in the majority of adults over fifty — and partly from age-related degradation of the SCN’s circadian amplitude, weakening the environmental synchronization signals that drive melatonin production in the first place.
Reduced melatonin with aging contributes to the classic changes in older adults’ sleep architecture: reduced sleep efficiency, more nighttime awakenings, earlier sleep timing, reduced slow-wave sleep — all consistent with melatonin’s role in sleep maintenance eroding.
The practical strategies for supporting melatonin production with age center on three levers: maximizing daytime light exposure to maintain SCN amplitude, minimizing evening blue light to preserve whatever’s left of the synthesis window, and supplying the biochemical precursors melatonin synthesis needs.
Daytime bright light exposure is arguably more important than reducing nighttime light for maintaining strong circadian amplitude in older adults. The SCN’s circadian amplitude — the magnitude of the 24-hour oscillation driving melatonin production — depends on enough daytime photic input to maintain contrast between day and night signals.
Older adults spending most of the day in indoor lighting (typically 100-500 lux) get insufficient photic input for optimal SCN amplitude — outdoor sunlight runs 10,000-100,000 lux, two to three orders of magnitude more intense. Getting 30-60 minutes of outdoor bright light within the first two hours of waking provides the strongest SCN zeitgeber (time-giver) stimulus available, and multiple intervention studies link it to both better sleep quality and higher nocturnal melatonin.
Tryptophan — the amino acid precursor for both serotonin and melatonin — needs to be adequately available for normal melatonin synthesis. Tryptophan-containing foods, including turkey, eggs, dairy, nuts, and seeds, supply the raw material for the serotonin-melatonin pathway. Serotonin availability in the pineal gland during the day determines how much substrate is on hand for nocturnal melatonin synthesis.
Morning light exposure also boosts brain serotonin synthesis through effects on tryptophan hydroxylase, the rate-limiting enzyme in serotonin production — another mechanism through which morning bright light supports mood and, downstream, subsequent melatonin production.
Melatonin Supplementation: When, How Much, and What Type
Melatonin supplements are the most widely used over-the-counter sleep aids in the United States, generating billions in annual sales largely on the strength of their sleep-promoting effects. The actual science is considerably more nuanced than standard dosing advice suggests — most people take doses far higher than what’s shown to work best, at timing that produces suboptimal results.
The dose question is the most striking place where popular practice diverges from pharmacological reality. The typical over-the-counter dose in the US runs 3-10 mg. Studies consistently show physiological doses of 0.1-0.3 mg produce blood melatonin levels in the high-normal range for nighttime production.
A 1996 study in Sleep Medicine Reviews by Richard Wurtman’s group at MIT found 0.3 mg as effective as 3 mg for sleep onset — with the advantage that lower doses didn’t produce the “hangover” effect of supraphysiological dosing and didn’t suppress the body’s own melatonin production through feedback inhibition.
Higher doses push blood melatonin levels 10-100 times above normal nighttime values, activating physiological responses at the melatonin receptor well beyond normal sleep-related signaling, and may actually desensitize receptors with regular use.
Timing matters more than dose for most applications. For sleep onset, melatonin should be taken 30-60 minutes before the desired sleep time and, optimally, 2 hours after DLMO — which typically works out to 30-90 minutes before habitual bedtime for people with normal circadian timing. For jet lag, timing relative to the destination time zone’s night is critical; melatonin taken at the wrong phase can actually worsen circadian adjustment instead of helping it.
For shift workers, the timing protocol to support daytime sleep needs deliberate phase-mapping, different from standard sleep-promoting use.
Extended-release melatonin formulations (marketed as Circadin in Europe) fit sleep maintenance problems more physiologically — they mimic the sustained nocturnal melatonin profile instead of a sharp peak and decline, more relevant for people who fall asleep fine but wake at 3-4 AM.
Which is precisely the pattern Tom — the opening case — experienced. Sleep maintenance, not sleep onset, was the problem, suggesting extended-release at physiological doses would suit him better than the immediate-release 5 mg tablets he’d briefly tried without any benefit.
Natural variability in exogenous melatonin absorption is enormous — bioavailability varies fivefold between individuals due to differences in first-pass hepatic metabolism. A 3 mg dose in one person can produce the same blood level as 0.5 mg in another. This individual variability is part of why the population-level dose-response curve for melatonin supplementation is so poorly defined — and why what one person needs tells you almost nothing about the next.
Practical Melatonin Optimization Protocol
The protocol for optimizing melatonin is more about managing the environment than supplementing — the goal is supporting the body’s own production through appropriate light-dark cycling, since endogenous production at physiological timing and concentration beats supplementation in all but a handful of specific circumstances.
- Morning bright light exposure: 20-60 minutes outdoors within the first 2 hours of waking, without sunglasses when safe and comfortable. The single highest-impact intervention for circadian amplitude and melatonin support.
- Blue light management in the evening: 2 hours before intended sleep time, shift to warm-spectrum lighting (2700K or lower color temperature, amber LED bulbs). Wear blue-light-blocking glasses if screen use continues. Cut overall light intensity.
- Sleep environment darkness: complete darkness in the sleeping environment. Blackout curtains or a sleep mask eliminate light-mediated melatonin suppression during the critical early nighttime window when the largest melatonin rise happens. Even dim light — 15-200 lux — can suppress melatonin by 50% in some people.
- Consistent sleep timing: the SCN’s circadian amplitude depends on consistent 24-hour zeitgeber entrainment. Variable sleep timing, even on weekends, reduces the circadian contrast driving melatonin production. Keeping sleep timing within 30-60 minutes day to day preserves circadian regularity.
- Avoid eating in the 3 hours before sleep: caloric intake triggers metabolic signaling that works against the metabolic quiescence melatonin initiates. Late eating specifically impairs the nocturnal glucose and insulin dynamics melatonin normally orchestrates.
- Temperature reduction: dropping core body temperature is a trigger for melatonin rise and sleep onset — sleeping in a cool environment (65-68°F) supports the temperature-melatonin relationship that facilitates sleep maintenance.
Where Melatonin Comes Q&A
A legitimate concern, and it depends heavily on dose. At physiological doses of 0.1-0.5 mg, exogenous melatonin doesn’t meaningfully suppress endogenous production, because those doses stay within the normal physiological blood-level range. At supraphysiological doses of 3-10 mg — the typical commercial dose — animal studies and some human data suggest receptor desensitization and feedback suppression of pineal production can occur with regular use.
The practical recommendation: the clinical literature has moved toward smaller amounts and extended-release rather than bigger immediate-release tablets, and the primary focus belongs on the environmental factors that suppress natural melatonin production rather than on supplementing around them indefinitely.
Q: Can children and teenagers safely take melatonin?
Children naturally produce high melatonin levels, and the indiscriminate use of melatonin supplements in kids — which has climbed sharply in recent years — isn’t supported by evidence of safety or efficacy for typical childhood sleep difficulties.
Low-dose melatonin appears safe for specific pediatric applications, including sleep difficulties in children with autism spectrum disorder, ADHD, or other neurodevelopmental conditions where the circadian system is genuinely disrupted, with pediatric studies supporting 0.5-3 mg doses for those specific applications.
For typical sleep difficulties in neurotypical children, behavioral sleep interventions — addressing light exposure, consistent bedtimes, screen time — have more evidence behind them and no risk of interfering with the endogenous hormonal environment during a developmental period when melatonin levels are supposed to run high.
Q: What is “social jet lag” and how does it affect melatonin?
Social jet lag refers to the mismatch between biological circadian timing — set by genetics and light exposure patterns — and social scheduling requirements. Someone whose natural sleep timing runs midnight to 8 AM but who has to wake at 6 AM for work is living with a two-hour gap between biological and social time.
That mismatch shifts melatonin timing relative to the social schedule — the rise and peak happen later than the required sleep window allows — producing chronic partial sleep deprivation and circadian disruption on weekday schedules, often partly compensated on weekends by sleeping in. The pattern produces systematic melatonin suppression at the wrong times and contributes to the broader health consequences of circadian misalignment.
Morning bright light exposure is the most effective intervention for advancing circadian phase in night-owl chronotypes who need to sync up with early social schedules.
Q: Does melatonin help with anxiety and mood in addition to sleep?
Melatonin has shown anxiolytic effects across multiple clinical settings — partly through GABA-A receptor modulation (a mechanism similar to benzodiazepines at pharmacological doses), partly through effects on stress axis activity, and partly through sleep improvement that reduces anxiety directly. A systematic review in Sleep Medicine Reviews found melatonin reduced preoperative anxiety in surgical patients at least as effectively as midazolam, a benzodiazepine, with a better safety profile.
The seasonal pattern of melatonin production — longer nighttime elevation in winter, tracking longer nights — connects to seasonal affective disorder (SAD), where winter melatonin over-expression relative to the photoperiod may contribute to depressive symptoms in susceptible people. Bright light therapy for SAD works partly by truncating that extended winter melatonin window.
Q: Should I take melatonin every night as a preventive health strategy?
For most people under 50 with intact circadian rhythms and no specific sleep complaint, the better investment is the environmental and behavioral practices that preserve strong natural melatonin production. These beat supplementation because they produce melatonin at physiologically appropriate timing and concentration, with the full nocturnal rhythm intact rather than a supplement-induced spike.
For people over 60 with documented age-related melatonin decline and associated sleep quality issues, extended-release melatonin at the small amounts studied in that age group, taken at the right time, has a favorable evidence base and risk profile. For shift workers or frequent transmeridian travelers, targeted melatonin use for phase management is evidence-supported. But “prophylactic daily melatonin for general health” is a strategy running well ahead of the current evidence.
Melatonin and the Gut: Another Bidirectional Axis
A frequently overlooked piece of melatonin biology: the gastrointestinal tract contains 400 times more melatonin than the pineal gland — produced locally by enterochromaffin cells lining the gut mucosa in response to food intake.
This gut-derived melatonin is distinct from pineal melatonin in what triggers it (food rather than darkness) and its local rather than circadian function, but it feeds into the same pool of melatonin receptors throughout the body and carries the same anti-inflammatory and antioxidant properties as the pineal-produced version.
Gut melatonin regulates intestinal motility, modulates intestinal immune responses, protects gut mucosa from oxidative damage, and helps maintain intestinal tight junction integrity. The melatonin produced after eating is one mechanism through which food intake signals the gut immune system that current luminal contents are safe and shouldn’t trigger an inflammatory response — a form of molecular tolerance.
When gut melatonin production is impaired — through gut dysbiosis, inflammatory damage to enterochromaffin cells, or nutritional depletion of tryptophan, the shared precursor for both gut and pineal melatonin — gut barrier integrity can suffer through this pathway independent of what’s happening with pineal melatonin.
This gut-melatonin connection has clinical relevance for people dealing with both sleep problems and gut symptoms, who show up together more often than pure chance would predict. The tryptophan supply chain underlies both systems: tryptophan absorbed from the diet converts to serotonin in the gut (then to melatonin by gut enterochromaffin cells) and also travels in the blood to the brain, where it contributes to central serotonin and, ultimately, pineal melatonin synthesis.
Adequate dietary tryptophan — eggs, turkey, dairy, nuts, seeds — supports both gut and brain melatonin production at the same time. States of gut malabsorption that reduce tryptophan bioavailability, including celiac disease and inflammatory bowel disease, can reduce melatonin production by depleting that shared precursor.
Melatonin and Reproductive Health
Melatonin’s role in reproductive biology reaches beyond its general anti-aging and antioxidant functions into specific regulation of gonadal function and oocyte quality — increasingly relevant given rising infertility rates in developed countries and the well-documented impact of circadian disruption on reproductive outcomes.
In the ovary, melatonin concentrates in follicular fluid at levels substantially higher than in blood, protecting developing oocytes from oxidative damage during the energy-intensive meiotic divisions of folliculogenesis. The ovarian follicle expresses melatonin receptors on granulosa cells, and melatonin modulates how the follicle responds to FSH stimulation, promoting granulosa cell survival and estradiol production.
A 2017 study in the Journal of Pineal Research found women undergoing IVF with higher nighttime melatonin levels had significantly better fertilization rates and embryo quality scores than those with lower melatonin. Several fertility centers now use melatonin supplementation as an adjunct in IVF protocols specifically based on this oocyte-protective evidence.
In men, testicular melatonin receptors regulate testosterone production in a pattern that’s seasonally modulated in photoperiod-sensitive mammals — a seasonal reproductive timing function that’s vestigial in humans, but potentially still relevant to how circadian melatonin patterns influence testosterone levels. More clinically relevant is melatonin’s protection of sperm from oxidative damage — sperm are particularly vulnerable to lipid peroxidation and oxidative DNA damage given their high polyunsaturated fatty acid content and their inability to repair DNA once spermatogenesis is complete.
Melatonin in seminal plasma concentrates locally to protect sperm from reactive oxygen species, and men with lower seminal plasma melatonin show higher rates of sperm DNA fragmentation and reduced sperm motility across several studies. Optimizing conditions for strong melatonin production — adequate darkness during sleep, consistent sleep timing, adequate tryptophan intake — is therefore relevant to male fertility too, on top of the broader health dimensions already covered.
Melatonin is not what you take when you can’t sleep. Melatonin is what happens when your biology is working correctly — a precisely timed, precisely dosed signal of darkness that coordinates repair, immunity, metabolism, and cellular protection across every tissue in your body. The supplement you take is a crude approximation of a sophisticated hormonal event. The environmental practices that enable that event are the actual intervention.
Tom, once he started taking his 3 AM wake-ups seriously, had his DLMO measured in a clinical sleep study. Shifted three hours later than normal for his age and chronotype — he was a physiological night owl trying to live as a morning person, melatonin onset landing around midnight instead of 10 PM. His evening light environment wasn’t helping: bright LED overhead lighting until 11 PM, smartphone use in bed, a bathroom with a harsh white LED vanity light.
The interventions were almost insultingly plain for someone used to complex medical solutions: amber bulbs in the evening, blue-light-blocking glasses after 9 PM, a blackout curtain, a consistent wake time with morning outdoor light. Four months later he was sleeping through the night. His blood pressure normalized. His fasting glucose returned to normal. He said he felt like himself again. The melatonin system had been trying to tell him what it needed the whole time. He’d finally started listening.
References
Editorial StandardsCorrectionsMedical DisclaimerAbout Our ContentAffiliate DisclosureSite Map